According to Zhitong Finance App News, China Resources Pharmaceutical (03320) announced that in the first half of 2026, Tianshi Pharmaceutical achieved total operating revenue of RMB 4.201 billion, down 2.03% year on year; net profit attributable to shareholders of listed companies of RMB 893 million, up 15.23% year on year; net profit attributable to shareholders of listed companies (after deducting non-recurring income or loss) of RMB 870 million, an increase of 36% year on year; basic profit per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.